RECORD // Company

Gossamer Bio, Inc.

Built 2026-11-22T00:42:43Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (3 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (2)
SEC EDGAR (1)
Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001728117-26-000114

ItemValuePeriodFormFiledAccessionReport
Revenue$38,431,0003 months ended 2026-09-3010-Q2026-11-100001728117-26-0001142026-11-22 00:42 UTCReport an error
Net income (loss)$-48,072,0003 months ended 2026-09-3010-Q2026-11-100001728117-26-0001142026-11-22 00:42 UTCReport an error
Interest expense$2,464,0003 months ended 2026-09-3010-Q2026-11-100001728117-26-0001142026-11-22 00:42 UTCReport an error
Cash and cash equivalents$51,189,000at 2026-09-3010-Q2026-11-100001728117-26-0001142026-11-22 00:42 UTCReport an error
Contract liabilities, current$0at 2026-09-3010-Q2026-11-100001728117-26-0001142026-11-22 00:42 UTCReport an error
Contract liabilities, noncurrent$0at 2026-09-3010-Q2026-11-100001728117-26-0001142026-11-22 00:42 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001728117
Ticker
GOSS
EIN
475461709
CUSIP
38341P102
Record ID
sx:sec:0001728117

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:42 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 00:42 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 00:42 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:42 UTCReport an error
Business address3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 921212026-11-16SEC EDGAR company profile2026-11-22 00:42 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:42 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$48,471,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 00:42 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-170,370,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:42 UTCReport an error
Total assets (at 2025-12-31)$172,249,0002025-12-3110-K, XBRL Assets2026-11-22 00:42 UTCReport an error
Stockholders' equity (at 2025-12-31)$-122,760,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:42 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$37,732,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:42 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-171,266,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:42 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$79,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:42 UTCReport an error
Long-term debt (at 2024-12-31)$02024-12-3110-K, XBRL LongTermDebtNoncurrent2026-11-22 00:42 UTCReport an error
Operating lease liabilities (at 2025-12-31)$4,398,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:42 UTCReport an error
Form D total offering amount (D filed 2026-09-04)$150,000,0002026-09-04D2026-11-22 00:42 UTCReport an error
Form D total amount sold (D filed 2026-09-04)$25,000,0002026-09-04D2026-11-22 00:42 UTCReport an error
Form D industry groupBiotechnology2026-09-04D2026-11-22 00:42 UTCReport an error
Form D revenue rangeDecline to Disclose2026-09-04D2026-11-22 00:42 UTCReport an error
Form D date of first sale2026-08-202026-09-04D2026-11-22 00:42 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-10)On November 10, 2026, Gossamer Bio, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release attached as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of…2026-11-10SEC EDGAR 8-K 0001728117-26-000116 (text as filed, excerpt)2026-11-22 00:42 UTCReport an error
8-K Item 5.07, Submission of Matters to a Vote of Security Holders (filed 2026-10-28)The following is a brief description of the matter voted upon at the special meeting of stockholders of Gossamer Bio, Inc. (the “Company”) held on October 27, 2026 (the “Special Meeting”) and the number of votes cast for or against, the number of abstentions and the number of broker non-votes with respect to the matter, as applicable. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Company’s definitive proxy statement relating to the Special Meeting, dated as of and filed with the U.S. Securities and Exchange Commission on September 16, 2026 (the “Proxy Statement”). The approval, in accordance with Nasdaq Listing Rules 5635(c) and…2026-10-28SEC EDGAR 8-K 0001728117-26-000109 (text as filed, excerpt)2026-11-22 00:42 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-28)On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1), and the minimum bid price matter is now closed. The letter was pursuant to a previous letter received on April 8, 2026 from the Listing Qualifications Department of Nasdaq, indicating, as previously reported, that the Company was not then in compliance with the minimum bid price requirement because its common stock had failed to maintain a minimum bid…2026-09-28SEC EDGAR 8-K 0001728117-26-000106 (text as filed, excerpt)2026-11-22 00:42 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-23)On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“PAH”). This is the Company’s first NDA submission. The NDA is supported by the Company’s Phase 3 PROSERA Study as one adequate and well-controlled clinical investigation, together with confirmatory evidence from the Company’s Phase 2 TORREY Study and supportive analyses. The NDA submission follows the Company’s Pre-NDA Type B meeting with the FDA in June 2026 and the FDA’s official written meeting minutes, in which the FDA characterized the…2026-09-23SEC EDGAR 8-K 0001728117-26-000104 (text as filed, excerpt)2026-11-22 00:42 UTCReport an error
Largest institutional holder #1 (13F as filed): D. E. Shaw & Co., Inc.$6,741,8982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error
Largest institutional holder #2 (13F as filed): 683 Capital Management, LLC$6,452,1342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error
Largest institutional holder #3 (13F as filed): DeepCurrents Investment Group LLC$6,026,4112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error
Largest institutional holder #4 (13F as filed): Context Capital Management, LLC$4,764,5872026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error
Largest institutional holder #5 (13F as filed): Worth Venture Partners, LLC$4,117,9432026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error
Largest institutional holder #6 (13F as filed): Kalehua Capital Management LLC$3,670,3702026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error
Largest institutional holder #7 (13F as filed): AQR CAPITAL MANAGEMENT LLC$2,572,6972026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error
Largest institutional holder #8 (13F as filed): WOLVERINE ASSET MANAGEMENT LLC$2,122,4752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error
Largest institutional holder #9 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$1,914,2812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error
Largest institutional holder #10 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$1,553,6442026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:42 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.